Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Moleculin Biotech, Inc. (Nasdaq: MBRX), a clinical-stage pharmaceutical firm, announced its participation in the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care from September 8-10, 2022, at the Roswell Park Comprehensive Cancer Center, Buffalo, NY. Presentations will include The Value of Collaboration in Clinical Development by CEO Walter Klemp and Translating Preclinical Research Into Clinical Trials by Dr. Robert Shepard. The company focuses on drug candidates for resistant tumors, including Annamycin for leukemia and WP1066 for brain tumors.
- None.
- None.
HOUSTON, Sept. 8, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will virtually present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, NY September 8-10, 2022.
Details of the presentations are as follows:
Title: The Value of Collaboration in Clinical Development: Experience from Poland
Presenter: Walter Klemp, President and Chief Executive Officer
Session 2: Opportunities for International Collaborations & Funding
Date & Time: Friday, September 9 at 12:05 PM ET
Title: Translating Preclinical Research Into Clinical Trials
Presenter: Robert Shepard, MD, FACP, Medical Advisor
Session B: Translational Research
Date & Time: Saturday, September 10 at 11:10 AM ET
For more information about the conference, visit: www.roswellpark.org/msc-symposium.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator designed to be capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers; and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122, for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, whether the results of Moleculin's preclinical models can be replicated in human trials, Moleculin's ability to conduct a potential future Phase 2 COVID-19 clinical study, Moleculin's ability to identify and attract collaborators for additional clinical trials of WP1122, and the ability for WP1122 to be shown safe and effective in humans. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-selected-to-present-at-the-2nd-annual-marie-sklodowska-curie-symposium-on-cancer-research-and-care-301620215.html
SOURCE Moleculin Biotech, Inc.
FAQ
What is the significance of the 2nd Annual Marie Sklodowska-Curie Symposium for MBRX?
When will Moleculin Biotech present at the symposium?
Who is presenting on behalf of MBRX at the symposium?
What are some drug candidates being developed by MBRX?
What date is MBRX's presentation on clinical development collaboration?
